Hatem Soliman, MD
Researcher

Hatem Soliman, MD

Academic Rank: Associate Member

Overview

Discipline

    • Breast Oncology
    • Tumor Biology
    • Immunology

Education & Training

    • Medical College of Georgia, MD
    • University of South Florida, Resident - Internal Medicine
    • University of South Florida, Fellow - Hematology/Oncology
Research

Dr. Soliman's research focuses on the development of new immunotherapy treatments (vaccines, immune modulating drugs) in the treatment of breast cancer.

Publications

  • Cox K, Alford B, Soliman H. Emerging Therapeutic Strategies in Breast Cancer. South Med J. 2017 Oct;110(10):632-637. Pubmedid: 28973703.
  • Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay. JAMA Oncol. 2017 Oct;e173470. Pubmedid: 29075751.
  • Tauro M, Shay G, Sansil SS, Laghezza A, Tortorella P, Neuger AM, Soliman H, Lynch CC. Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther. 2017 Mar;16(3):494-505. Pubmedid: 28069877. Pmcid: PMC5337166.
  • Prabhakaran S, Rizk VT, Ma Z, Cheng CH, Berglund AE, Coppola D, Khalil F, Mulé JJ, Soliman HH. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. Breast Cancer Res. 2017 Jun;19(1):71. Pubmedid: 28629479. Pmcid: PMC5477261.
  • Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 2017 Jun;19(1):75. Pubmedid: 28666457. Pmcid: PMC5493088.
  • Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017 Feb;19(1):18. Pubmedid: 28183331. Pmcid: PMC5301372.
  • Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2(+) breast cancer: Current landscape and future perspectives. Cancer Treat Rev. 2017 Dec;61:107-115. Pubmedid: 29125981.
  • Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S. Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. J Adolesc Young Adult Oncol. 2017 Aug. Pubmedid: 28777007.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Ne. 2017 Apr;15(4):433-451. Pubmedid: 28404755.
  • George B, Kelly K, Ko A, Soliman H, Trunova N, Wainberg Z, Waterhouse D, O'Dwyer P. P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct;11(10S):S211-S212. Pubmedid: 27676532.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Mar;14(3):324-354. Pubmedid: 26957618.
  • Yardley DA, Reeves J, Dees EC, Osborne C, Paul D, Ademuyiwa F, Soliman H, Guthrie T, Andersen J, Krekow L, Choksi J, Daniel B, Danso M, Favret A, Oommen S, Brufsky A, Bromund JL, Lin Y, Ibrahim AB, Richards PD. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clin Breast Cancer. 2016 Dec;16(6):471-479.e1. Pubmedid: 27569274.
  • Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther. 2016 Dec;10:101-112. Pubmedid: 28053544. Pmcid: PMC5189972.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Yang L, Song T, Chen L, Soliman H, Chen J. Nucleolar repression facilitates initiation and maintenance of senescence. Cell Cycle. 2015 Nov;14(22):3613-3623. Pubmedid: 26505814. Pmcid: PMC4825723.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Ne. 2015 Dec;13(12):1475-1485. Pubmedid: 26656517.
  • Soliman H, Mediavilla-Varela M, Antonia SJ. A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. Breast Cancer (Dove Med Press). 2015 Dec;7:389-397. Pubmedid: 26719725. Pmcid: PMC4687618.
  • Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ. Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park). 2015 Dec;29(12):990-1002. Pubmedid: 26680224.
  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast cancer version 2.2015. J Natl Compr Canc Ne. 2015 Apr;13(4):448-475. Pubmedid: 25870381.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557. Pmcid: PMC4226672.
  • Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL. The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition. Front Immunol. 2014 Oct;5:429. Pubmedid: 25368611. Pmcid: PMC4202790.
  • Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 2014 Feb;9(2):e88557. Pubmedid: 24551119. Pmcid: PMC3925108.
  • Menanteau-Ledouble S, Soliman H, Kumar G, El-Matbouli M. Use of in vivo induced antigen technology to identify genes from Aeromonas salmonicida subsp. salmonicida that are specifically expressed during infection of the rainbow trout Oncorhynchus mykiss. BMC Vet Res. 2014 Dec;10:298. Pubmedid: 25495705. Pmcid: PMC4269963.
  • Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Ne. 2014 Apr;12(4):542-590. Pubmedid: 24717572.
  • Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia S. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013 Sep;14(9):860-868. Pubmedid: 23917542. Pmcid: PMC3909555.
  • Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immun. 2013 May;62(5):829-837. Pubmedid: 23344392. Pmcid: PMC4501769.
  • Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013 Mar;2(3):e23428. Pubmedid: 23802083. Pmcid: PMC3661168.
  • Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2013 Jul;11(7):753-760. Pubmedid: 23847214. Pmcid: PMC3991132.
  • Soliman H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control. 2013 Jan;20(1):17-21. Pubmedid: 23302903.
  • Joh JE, Esposito NN, Kiluk JV, Laronga C, Khakpour N, Soliman H, Catherine Lee M. Pathologic Tumor Response of Invasive Lobular Carcinoma to Neo-adjuvant Chemotherapy. Breast J. 2012 Nov;18(6):569-574. Pubmedid: 23034096.
  • Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist. 2012 Jun;16(11):1520-1526. Pubmedid: 22016474. Pmcid: PMC3233285.
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012 Jul;10(7):821-829. Pubmedid: 22773798. Pmcid: PMC3753191.
  • Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-991. Pubmedid: 20420527. Pmcid: PMC3146364.
  • Soliman H. Developing an effective breast cancer vaccine. Cancer Control. 2010 Jul;17(3):183-190. Pubmedid: 20664516.
  • Soliman H, Ferrari A, Thomas D. Sarcoma in the young adult population: an international view. Semin Oncol. 2009 Jun;36(3):227-236. Pubmedid: 19460580.
  • Soliman H, Agresta S. Current issues in adolescent and young adult cancer survivorship. Cancer Control. 2008 Jan;15(1):55-62. Pubmedid: 18094661.
  • Ling J, Pi W, Bollag R, Zeng S, Keskintepe M, Soliman H, Krantz S, Whitney B, Tuan D. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells. J Virol. 2002 Mar;76(5):2410-2423. Pubmedid: 11836419.
  • Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 16(4):354-359. Pubmedid: 20693847. Pmcid: PMC3850167.